Automated detection of neutropenia using non‐invasive video microscopy of superficial capillaries by Pablo-Trinidad, Alberto et al.
                                                                    
University of Dundee
Automated detection of neutropenia using noninvasive video microscopy of superficial
capillaries
Pablo-Trinidad, Alberto; Butterworth, Ian; LedesmaCarbayo, María J.; Vettenburg, Tom;
SánchezFerro, Álvaro; Soenksen, Luis
Published in:







Link to publication in Discovery Research Portal
Citation for published version (APA):
Pablo-Trinidad, A., Butterworth, I., LedesmaCarbayo, M. J., Vettenburg, T., SánchezFerro, Á., Soenksen, L.,
Durr, N. J., Muñoz Barrutia, A., Cerrato, C., Humala, K., Fabra Urdiol, M., Del Rio, C., Valles, B., Chen, YB.,
Hochberg, E. P., CastroGonzález, C., & Bourquard, A. (2019). Automated detection of neutropenia using non
invasive video microscopy of superficial capillaries. American Journal of Hematology, 94(8), E219-E222.
https://doi.org/10.1002/ajh.25516
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 23. Jun. 2020
Automated detection of neutropenia using non-invasive video 
microscopy of superficial capillaries  
Alberto Pablo-Trinidad1,2, Ian Butterworth2,3, María J. Ledesma-Carbayo1, Tom Vettenburg3, 
Álvaro Sánchez-Ferro2,3, Luis Soenksen4, Nicholas J. Durr5, Arrate. Muñoz Barrutia6, Carolina 
Cerrato7, Karem Humala7, Marta Fabra Urdiol7, Candice Del Rio8, Betsy Valles8, Yi-Bin Chen8, 
Ephraim P. Hochberg8, Carlos Castro-González1,2,3* & Aurélien Bourquard1,2,3* 
1. Biomedical Image Technologies, Universidad Politécnica de Madrid and CIBER-BBN,
Madrid, Spain
2. Leuko Labs Inc., Cambridge, MA, USA
3. Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge,
MA, USA
4. Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge,
MA. USA
5. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA
6. Bioengineering and Aerospace Engineering Carlos III University of Madrid Madrid, Spain
7. Departamento de Hematología, Hospital Universitario La Paz, Madrid, Spain
8. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
* These authors contributed equally
To the Editor: 
Cancer patients undergoing cytotoxic chemotherapy are at elevated risk of developing serious infections1. 
The risk of developing these infections increases when white blood cell (WBC) counts, particularly the 
absolute neutrophil counts (ANC), are reduced. This reduction in neutrophil counts, the most abundant 
white-blood-cell subtype, is referred to as neutropenia, with these infection episodes termed febrile 
neutropenia (FN). Patients have a high risk of developing FN during sustained severe neutropenia1 
(ANC<500/µL), which is a common side effect of cytotoxic chemotherapies. FN occurs frequently, 
currently in approximately one in six of all chemotherapy patients2, and it is associated with a high rate of 
mortality3, where 11% of patients die after one or several hospitalizations4,5. In the US alone, the 
associated cost due to such hospitalizations accounts for $2.7B dollars annually2, contributing to up to 
40% of the total cost of cancer treatments6.  
Early detection of severe neutropenia can be key to preventing FN. Timely detection could enable 
preventive therapies, such as Granulocyte-Colony Stimulating Factors (GCSF)7 or prophylactic 
antibiotics, to be administered. Unfortunately, current neutrophil monitoring options are inadequate to 
monitor severe neutropenia with sufficient frequency to allow for early detection and therapy 
optimization. Their reliance on the extraction and analysis of blood samples, which requires trained 
medical oversight, typically limits this testing to clinical settings. Cost-effective high frequency 
monitoring of this parameter, therefore, requires a new method that can be used by outpatients with 
minimal risk. 
To address this unmet need, we propose the first non-invasive technology that can automatically screen 
patients for severe neutropenia without requiring blood draws, thus enabling patients to have more 
frequent access to this test. Our proposed non-invasive device is a compact microscopy system that can 
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acquire high-resolution, high-frame-rate videos of superficial capillaries (Figure S1)8, coupled with an 
automated software pipeline that can analyze those videos for a measurement of neutropenia. This design 
potentially opens the door to the use of such instrumentation in the patient’s home. We conducted a 
clinical study at two independent hospitals to assess the ability of our device and algorithm to detect 
severe neutropenia in chemotherapy patients undergoing standard therapy. In previously reported work8, 
we demonstrated an initial proof-of-concept of this principle using a small set of nailfold capillary video 
samples8, which were manually analyzed through visual inspection by human experts. Here, we further 
demonstrated and validated a fully automated software analysis pipeline and extended our results to a 
larger cohort of 44 patients.  
The individuals enrolled in our study were selected from patients undergoing high-dose chemotherapy 
followed by Autologous Stem Cell Transplantation (ASCT) at the Massachusetts General Hospital 
(MGH) Boston, MA, USA, or at Hospital Universitario La Paz (HULP), Madrid, Spain. This specific 
patient population was selected due to its clinical relevance and highly standardized regimen which 
allows for predictable evolution of neutrophil count dynamics, ensuring a transition from baseline values 
(ANC>500/µL) to severe neutropenia (ANC<500/µL), as well as an opportunity to acquire multiple video 
samples at different time points (Figure S2). The protocol was approved by the corresponding IRB boards 
for a total of 44 patients to be included in this study (Supplementary Methods). 
From the 44 enrolled subjects, video sessions containing at least one suitable capillary in their field of 
view were collected (Supplementary Methods) at different stages of the ASCT treatment (Figure S2). 
Specifically, a technical operator ensured that at least one capillary fulfilled the required quality criteria 
for analysis8. This resulted in a total of 115 imaging sessions from 42 subjects, with an average of three 
sessions per subject. Each imaging session is associated with a reference blood test performed by the 
gold-standard clinical-laboratory analyzer whose values, including the reference ANCs, are provided in 
the Supplementary Methods (Figure S3). To confirm the findings of our previous work correlating the 
number of capillaries analyzed with the classification accuracy8, we evaluated the diagnostic performance 
of our automatic pipeline on three distinct sets of imaging sessions: those that had at least one suitable 
capillary (all 115 imaging sessions from all 42 patients), at least two (100 imaging sessions from 38 
patients), or at least three (89 sessions from 35 patients). 
Following the acquisition of these sessions using our clinical prototype8, an automated software pipeline 
composed of several processing steps (Supplementary Methods) was designed to analyze the raw videos. 
The analysis of each video session produced a separate data point consisting in a unitless “Leuko Index”, 
which was used to classify severe-neutropenic cases (ANC<500/µL) from the rest (ANC>500/µL). To 
produce this index, our pipeline first detected nailfold capillaries in the corresponding video session, then 
counted passing optical-absorption gaps —which as discussed in Bourquard et al 20188 can be considered 
as proxies of flowing neutrophils — inside these capillaries, and finally averaged the individual capillary 
counts into one single value. Results were then compared against the gold-standard ANC values to 
determine performance in separating severely neutropenic patients (ANC<500/µL) from the rest 
(ANC>500/µL), giving the opportunity to calculate the rate of correctly-classified severe neutropenia 
cases (true positives) against the rate of false alarms (false positives).   
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The classification performance for all imaging sessions, with at least three suitable capillaries detected, 
yielded an Area Under the Curve (AUC)9 of 0.95 (Figure 1). The use of all imaging sessions with at least 
one suitable capillary yielded an AUC of 0.91 (Figure S4), whereas those containing at least two suitable 
capillaries yielded an AUC of 0.94 (Figure S5). The intra-measurement agreement of our method when 
using only one, two or three capillaries per imaging session was shown to increase as more capillaries 
were used (87% agreement when using 1 vs. 2 capillaries and 91.4% agreement when using 2 vs. 3 
capillaries), see Figure S6. Also, the classification performance improved with the amount of analyzed 
capillaries per session, with the percentage agreement increasing from 69.8% to 90.9% (Figure S6), which 




Caption: Figure 1: (Left) Non-invasive imaging sessions (red and blue markers), acquired from 
chemotherapy patients in our study, were automatically analyzed by our software pipeline to yield a 
“Leukoindex” result which can be used to perform a classification with respect to the corresponding 
gold-standard ANC values obtained from blood tests. Each classification result is associated either 
with a severe-neutropenic reference state (ANC<500; red markers) or above (ANC>500; blue 
markers). Results corresponding to imaging sessions containing at least three suitable capillaries 
are shown. (Right) Receiver Operating Characteristic (ROC) curve associated with this classification 
(AUC = 0.95, 35 patients, and N =89 imaging sessions). 
     
These results demonstrate, for the first time, that our non-invasive optical system (Figure S1), coupled 
with the proposed automated video analysis pipeline (Figure S7), is able to detect severe neutropenia with 
high accuracy in a patient cohort showing various degrees of ANC values (Figure S3), without the need 
for a blood draw. Future work includes the refinement of the device hardware to increase the number of 
suitable capillaries detected in a single session. The current analysis methods may also be adapted in the 
future to perform quantitative ANC measurements or differential detections of WBC subtypes.   
 
Overall, this work demonstrates that patients can be screened for severe neutropenia automatically and 
non-invasively without the need to draw blood. Our non-invasive blood analysis method opens the door 
to frequent, precise and personalized management of patients at risk for febrile neutropenia. 
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